Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
SI-BONE
(NASDAQ:SIBN)
Intraday
$15.00
-0.33
[-2.15%]
After-Hours
$15.00
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$15.00
-0.33
[-2.15%]
At close: May 13
$15.00
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Q1 2024 Earnings were released on Mon May 6th, after the market close
The most recent conference call was at 16:30 PM, 7 days ago
Click to view past webcast
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for SI-BONE Stock (NASDAQ:SIBN)
SI-BONE Stock (NASDAQ: SIBN)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Tuesday, May 07, 2024
Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $25
Benzinga Newsdesk
-
6 days ago
JMP Securities Reiterates Market Outperform on SI-BONE, Maintains $32 Price Target
Benzinga Newsdesk
-
6 days ago
SI-BONE Launches iFuse Bedrock Granite Implant System And Completes Inaugural Surgical Procedures
Benzinga Newsdesk
-
6 days ago
A Closer Look at 6 Analyst Recommendations For SI-BONE
Benzinga Insights
-
6 days ago
Needham Reiterates Buy on SI-BONE, Maintains $27 Price Target
Benzinga Newsdesk
-
6 days ago
Monday, May 06, 2024
SI-BONE Updates FY24 Worldwide Revenue Guidance From $162M-$165M To $164M-$166M Vs $163.631M Est.
Benzinga Newsdesk
-
May 6, 2024, 5:03PM
SI-BONE Q1 2024 GAAP EPS $(0.27) Beats $(0.32) Estimate, Sales $37.867M Beat $36.494M Estimate
Benzinga Newsdesk
-
May 6, 2024, 4:48PM
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights
-
May 6, 2024, 4:31PM
Wednesday, April 03, 2024
Needham Reiterates Buy on SI-BONE, Maintains $27 Price Target
Benzinga Newsdesk
-
Apr 3, 2024, 11:34AM
Thursday, March 28, 2024
Peeling Back The Layers: Exploring SI-BONE Through Analyst Insights
Benzinga Insights
-
Mar 28, 2024, 3:00PM
Piper Sandler Initiates Coverage On SI-BONE with Overweight Rating, Announces Price Target of $25
Benzinga Newsdesk
-
Mar 28, 2024, 12:19PM
Tuesday, February 27, 2024
SI-BONE shares are trading lower after the company reported mixed Q4 financial results.
Benzinga Newsdesk
-
Feb 27, 2024, 12:57PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Feb 27, 2024, 12:31PM
Morgan Stanley Maintains Overweight on SI-BONE, Raises Price Target to $26
Benzinga Newsdesk
-
Feb 27, 2024, 11:05AM
Beyond The Numbers: 4 Analysts Discuss SI-BONE Stock
Benzinga Insights
-
Feb 27, 2024, 10:00AM
Cantor Fitzgerald Maintains Overweight on SI-BONE, Maintains $25 Price Target
Benzinga Newsdesk
-
Feb 27, 2024, 9:12AM
Truist Securities Reiterates Buy on SI-BONE, Lowers Price Target to $24
Benzinga Newsdesk
-
Feb 27, 2024, 9:02AM
Monday, February 26, 2024
SI-BONE Sees FY24 Revenue $162M-$165M Vs $159.058M Est.
Benzinga Newsdesk
-
Feb 26, 2024, 4:38PM
Recap: SI-BONE Q4 Earnings
Benzinga Insights
-
Feb 26, 2024, 4:25PM
SI-BONE Q4 2023 GAAP EPS $(0.27) Misses $(0.26) Estimate, Sales $38.86M Beat $37.61M Estimate
Benzinga Newsdesk
-
Feb 26, 2024, 4:24PM
Earnings Scheduled For February 26, 2024
Benzinga Insights
-
Feb 26, 2024, 4:47AM
Friday, February 23, 2024
SI-BONE's Earnings Outlook
Benzinga Insights
-
Feb 23, 2024, 11:02AM
Tuesday, January 30, 2024
SI-BONE, Inc. Receives FDA 510(k) Clearance For A Smaller Diameter iFuse Bedrock Granite Implant With An Expanded Indication And Application
Benzinga Newsdesk
-
Jan 30, 2024, 8:38AM
Monday, January 08, 2024
SI-BONE Sees Prelim FY23 Revenue $138.5M-$138.7M Vs $136.14M Est.
Benzinga Newsdesk
-
Jan 8, 2024, 8:33AM
SI-BONE Sees Prelim Q4 Revenue $38.5M-$38.7M Vs $36.54M Est.
Benzinga Newsdesk
-
Jan 8, 2024, 8:32AM
Friday, December 22, 2023
What Analysts Are Saying About SI-BONE Stock
Benzinga Insights
-
Dec 22, 2023, 11:00AM
Truist Securities Maintains Buy on SI-BONE, Raises Price Target to $26
Benzinga Newsdesk
-
Dec 22, 2023, 10:09AM
Monday, December 04, 2023
What 5 Analyst Ratings Have To Say About SI-BONE
Benzinga Insights
-
Dec 4, 2023, 11:00AM
Needham Reiterates Buy on SI-BONE, Maintains $25 Price Target
Benzinga Newsdesk
-
Dec 4, 2023, 5:17AM
Tuesday, November 07, 2023
Cantor Fitzgerald Maintains Overweight Rating for SI-BONE: Here's What You Need To Know
Benzinga Insights
-
Nov 7, 2023, 12:00PM
Where SI-BONE Stands With Analysts
Benzinga Insights
-
Nov 7, 2023, 12:00PM
Cantor Fitzgerald Maintains Overweight on SI-BONE, Lowers Price Target to $25
Benzinga Newsdesk
-
Nov 7, 2023, 11:32AM
Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $25
Benzinga Newsdesk
-
Nov 7, 2023, 9:03AM
Needham Maintains Buy on SI-BONE, Lowers Price Target to $25
Benzinga Newsdesk
-
Nov 7, 2023, 6:14AM
Monday, November 06, 2023
SI-BONE Increases Its FY23 Revenue Guidance From $132M-$134M To $136M-$137M Vs $133.3M Est.
Benzinga Newsdesk
-
Nov 6, 2023, 5:04PM
SI-BONE Q3 2023 EPS $(0.25) Beats $(0.34) Estimate, Sales $34.01M Beat $32.38M Estimate
Benzinga Newsdesk
-
Nov 6, 2023, 4:19PM
Earnings Scheduled For November 6, 2023
Benzinga Insights
-
Nov 6, 2023, 8:24AM
Tuesday, September 26, 2023
Analyst Ratings for SI-BONE
Benzinga Insights
-
Sep 26, 2023, 1:00PM
Cantor Fitzgerald Reiterates Overweight on SI-BONE, Maintains $30 Price Target
Benzinga Newsdesk
-
Sep 26, 2023, 11:59AM
Tuesday, September 05, 2023
SI-BONE, Inc. Announces iFuse Bedrock Granite Implant System Compatibility With Certain Medtronic CD Horizon Solera 5.5/6.0 System Rods
Happy Mohamed
-
Sep 5, 2023, 4:22PM
Tuesday, August 22, 2023
Cantor Fitzgerald Reiterates Overweight on SI-BONE, Maintains $30 Price Target
Benzinga Newsdesk
-
Aug 22, 2023, 11:45AM
Tuesday, August 08, 2023
Cantor Fitzgerald Reiterates Overweight on SI-BONE, Maintains $30 Price Target
Benzinga Newsdesk
-
Aug 8, 2023, 2:17PM
SI-BONe shares are trading lower after the company reported Q2 financial results and issued FY23 revenue and worldwide revenue guidance.
Benzinga Newsdesk
-
Aug 8, 2023, 12:58PM
Truist Securities Maintains Buy on SI-BONE, Lowers Price Target to $31
Benzinga Newsdesk
-
Aug 8, 2023, 12:12PM
Analyst Ratings for SI-BONE
Benzinga Insights
-
Aug 8, 2023, 12:00PM
Needham Reiterates Buy on SI-BONE, Maintains $32 Price Target
Benzinga Newsdesk
-
Aug 8, 2023, 6:37AM
Monday, August 07, 2023
SI-BONE Raises FY23 Revenue From $128M-$131M To $132M-$134M Vs $130.03M Est
Benzinga Newsdesk
-
Aug 7, 2023, 4:51PM
SI-BONE Raises 2023 Worldwide Revenue Guidance From $128M-$131M To $132M-$134M
Benzinga Newsdesk
-
Aug 7, 2023, 4:39PM
SI-BONE Q2 EPS $(0.30) Beats $(0.41) Estimate, Sales $33.30M Beat $32.24M Estimate
Benzinga Newsdesk
-
Aug 7, 2023, 4:36PM
Earnings Scheduled For August 7, 2023
Benzinga Insights
-
Aug 7, 2023, 4:12AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch